Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-Center, Open-Label, Safety and Tolerability Study of Intravenous Administration of ST266 in Subjects With Confirmed COVID-19 Infection

NCT04720378 is registered in ClinicalTrials.gov with Noveome Biotherapeutics, formerly Stemnion as lead sponsor.

NCT NCT04720378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04720378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-Center, Open-Label, Safety and Tolerability Study of Intravenous Administration of ST266 in Subjects With Confirmed COVID-19 Infection
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Phase
Phase 1
Overall status
Completed
Start date
May 30, 2021
Completion date
May 3, 2022
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cytokine release syndrome